Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine

Drug and Alcohol Dependence

Volumn 82, Issue 1, 2006, Pages 25-31

  Compton, Peggy ^a   Ling, Walter ^b   Moody, David ^c   Chiang, Nora ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Bioavailability; Buprenorphine; Pharmacokinetics

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; OPIATE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACNE; ADULT; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CHILL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG FORMULATION; DRUG SOLUTION; DYSPEPSIA; FEMALE; FEVER; FLUSHING; GOOSEFLESH; HEADACHE; HICCUP; HOSPITAL PATIENT; HOT FLUSH; HUMAN; INSOMNIA; IRRITABILITY; LACRIMATION DISORDER; LEUKOCYTOSIS; MALE; MUSCLE CRAMP; MUSCLE HYPERTONIA; MYALGIA; NERVOUSNESS; NORMAL HUMAN; OPIATE ADDICTION; PH MEASUREMENT; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RESTLESSNESS; RHINITIS; RHINORRHEA; SIDE EFFECT; SKIN DISEASE; SNEEZING; SOMNOLENCE; STEADY STATE; STOMACH FUNCTION DISORDER; SWEATING; TABLET FORMULATION; TASTE DISORDER; TREMOR; VASODILATATION; VOMITING; XEROSTOMIA; YAWNING;

ADULT; BIOLOGICAL AVAILABILITY; BUPRENORPHINE; CROSS-OVER STUDIES; DOSAGE FORMS; DRUG ADMINISTRATION ROUTES; FEMALE; HUMANS; MALE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS;

EID: 33344471954     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2005.08.005     Document Type: Article

References (12)

1. P.G. Barnett, J.H. Rodgers, and D.A. Bloch A meta-analysis comparing burenorphine to methadone for treatment of opiate dependence Addiction 96 2001 683 690
2. S.M. Giacomuzzi, M. Ertl, G. Kemmler, H. Rossler, H. Hinterhuber, and M. Kurz Buprenorphine versus methadone maintenance treatment in an ambulant setting: a health-related quality of life assessment Addiction 98 2003 693 702
3. A. Leshner Accessing opiate dependence treatment medications: buprenorphine products in an office-based setting Drug Alcohol Depend. 70 2003 S103 S104
4. W. Ling, and D. Smith Buprenorphine: blending practice and research J. Subst. Abuse Treat. 23 2002 87 92
5. W. Ling, and D. Wesson Clinical efficacy of buprenorphine: comparisons to methadone and placebo Drug Alcohol Depend. 70 2003 S49 S57
6. D.E. Moody, M.H. Slawson, E.C. Strain, J.D. Laycock, A.C. Spanbauer, and R.L. Foltz A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determimnation of buprenorphine, its metabolite, norbuprenorphine, and a co-formulant, Naloxone, that is suitable for in vivo and in vitro metabolism studies Anal. Biochem. 306 2002 31 39
7. R.P. Nath, R.A. Upton, T. Everhart, P. Cheung, P. Shwonek, R.T. Jones, and J.E. Mendelson Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations J. Clin. Pharmacol. 39 1999 619 623
8. R.B. Resnick Food and Drug Administration approval of buprenorphine-naloxone for office treatment of addiction Ann. Intern. Med. 138 2003 360 361
9. K.J. Schuh, and C.E. Johanson Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet Drug Alcohol Depend. 56 1999 55 60
10. E.C. Strain, D.E. Moody, K.B. Stoller, S.L. Walsh, and G.E. Bigelow Relative bioavailability of different buprenrophine formulations under chronic dosing conditions Drug Alcohol Depend. 74 2004 37 43
11. S.L. Walsh, and T. Eissenberg The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic Drug Alcohol Depend. 70 2003 S13 S27
12. S.L. West, K.K. O'Neal, and C.W. Graham A meta-analysis comparing the effectiveness of buprenorphine and methadone J. Subst. Abuse 12 2000 405 415